Alaunos Therapeutics, Inc. quarterly report, Q1 FY2017

Business context and reporting period

This Form 10-Q covers the three months ended March 31, 2017. The filing identifies the registrant as ZIOPHARM Oncology, Inc. (the company now identified in the request as Alaunos Therapeutics, Inc.). ZIOPHARM was a clinical-stage biopharmaceutical company focused on immuno-oncology and graft-versus-host disease (GvHD); it had no approved products and reported minimal collaboration revenue.

Key financial metrics

Amounts are in millions of dollars unless otherwise noted.

Revenue was principally amortization of the Ares Trading collaboration upfront payment. The prior-year quarter also included revenue from Solasia and Predictive agreements that had since been fully recognized. The company had no commercial-product gross margin to report.

Cash used in investing activities was $0.358 million, mainly for equipment; financing provided $0.029 million. Cash declined by $14.606 million during the quarter. Working capital was $75.3 million, versus $89.1 million at year-end 2016. Total liabilities were $59.955 million, including $2.471 million of derivative liabilities and substantial deferred revenue; the filing does not report a conventional debt balance or debt-specific metrics.

Material changes versus the prior comparable period

• Operating loss widened by $1.925 million as R&D spending rose, despite lower G&A and collaboration revenue.
• R&D expense increased mainly with glioblastoma program work, the new National Cancer Institute collaboration, and increased staffing; lower spending on discontinued small-molecule programs partly offset the increase.
• Net loss included a $1.560 million noncash expense from the change in fair value of preferred-stock derivative liabilities; no comparable charge was reported in Q1 2016.
• Preferred-stock dividends of $4.171 million were paid in additional Series 1 preferred shares and increased the loss applicable to common stockholders. The company issued 3,216 preferred shares as quarterly dividends.
• Operating cash use improved year over year, but the cash balance fell from $81.053 million at December 31, 2016 to $66.447 million at March 31, 2017.

Outlook, management commentary, risks and contingencies

Management estimated that available cash would fund operations through the fourth quarter of 2017. It had no committed additional financing and stated that additional capital would be required for longer-term clinical and product development. Management concluded that substantial doubt existed about the company’s ability to continue as a going concern; financing availability, timing, and terms were uncertain. If funding or partnerships were unavailable, the company could curtail programs or reduce costs.

Planned 2017 development milestones included advancing Ad-RTS-IL-12 + veledimex in recurrent glioblastoma, pursuing a pivotal-trial path and combination and pediatric studies, and advancing CAR-T, NK-cell, TCR, and GvHD programs. These were forward-looking plans, not assurances of completion. The breast cancer study had been paused after collection of the desired biomarker data. Interim glioblastoma results were based on small patient groups and were not proof of efficacy or regulatory approval.

Key risks include clinical and regulatory uncertainty; adverse events and manufacturing challenges for novel cell and gene therapies; reliance on Intrexon, MD Anderson, and other collaborators; competition and intellectual-property risks; and dependence on future financing. The filing reported no legal matter management believed likely to have a material adverse financial effect as of March 31, 2017.

Contractual obligations totaled $26.038 million, including $18.939 million due within one year. This included $15.0 million in minimum MD Anderson payments due within one year and $6.875 million of CRADA obligations. Series 1 preferred stock carries a monthly dividend in additional preferred shares, conversion and liquidation rights, and potential common-stock dilution; its conversion is tied to specified U.S. product approvals and is subject to Nasdaq limits.

Important facts for investors to verify

• Whether financing or partnership arrangements were secured after the filing and how they affected the stated Q4 2017 cash runway and going-concern uncertainty.
• Subsequent cash burn, R&D spending, and the status and timing of the disclosed clinical and regulatory milestones.
• Updated clinical safety and efficacy data, particularly for glioblastoma, and whether planned studies proceeded.
• The current terms, accrued dividends, conversion or liquidation exposure, and potential dilution associated with Series 1 preferred stock.
• Whether contractual commitments, including MD Anderson funding and CRADA payments, changed or were fulfilled.